Apollomics, Inc. (APLM)

0,2109 +0,0027 (+1,30 %) À la clôture : 04:00PM EDT

Apollomics, Inc.

989 East Hillsdale Blvd
Suite 220
Foster City, CA 94404
United States
650 209 4055
https://www.apollomicsinc.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 45

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Guo-Liang Yu Ph.D.	Co-Founder, CEO & Executive Chairman	S.O.	S.O.	1963
Dr. Sanjeev Redkar MBA, Ph.D.	Co-Founder, President & Executive Director	S.O.	S.O.	1969
Dr. Matthew James Plunkett Ph.D.	Chief Financial Officer	S.O.	S.O.	1972
Dr. Kin-Hung Yu M.D.	Chief Medical Officer	S.O.	S.O.	1962
Dr. Chinglin Lai Ph.D.	Senior Vice President of Biostatistics & Data Management	S.O.	S.O.	S.O.

Les montants ont été établis en date du et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Apollomics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.